Decentralised clinical studies: collecting real-world data without the CRO price tag
These articles reflect our opinions and thoughts on the subjects covered, not purely factual statements. We encourage readers to consult multiple sources and their own medical professionals.
If you work in medical device market access, regulatory affairs, or clinical research, you have probably been told that collecting longitudinal patient outcomes requires hiring a Contract Research Organisation (CRO) and setting up expensive hospital trial sites. For post-market clinical follow-up (PMCF) and real-world evidence (RWE), that model is often unaffordable and unnecessary.
A decentralised study approach lets you collect validated patient-reported outcomes directly from patients in their everyday lives, without forcing clinics to manage binders of paperwork or requiring patients to travel for routine check-ins.
Plain English
- Decentralised study (DCT)
- A clinical investigation or registry where data collection (ePRO, symptom tracking) occurs remotely rather than at dedicated academic research sites.
- Electronic Patient-Reported Outcomes (ePRO)
- Validated clinical questionnaires (like Oxford scores, WOMAC, or KOOS) completed by participants on their own smartphones or computers.
- Product-linked follow-up
- Outcome data that explicitly connects the patient's recovery curve to a specific device SKU, batch, or surgical technique.
Why traditional site-based trials fail for post-market data
Under European MDR (EU 2017/745), manufacturers of Class IIa, IIb, and Class III devices must proactively collect post-market clinical data. Setting up traditional site-based studies for this purpose creates three major obstacles:
1. Prohibitive cost: Traditional CRO site management costs thousands of pounds per patient. For established devices or niche SKUs, full trial budgets destroy product margins.
2. Clinical site burnout: NHS and private surgeons are already overloaded. Asking them to complete 20-page electronic case report forms (eCRFs) for routine implants results in delayed recruitment and missing follow-up data.
3. Participant attrition: Requiring patients to travel back to a hospital at 6 months, 1 year, and 2 years just to fill in a paper questionnaire leads to trial drop-out rates exceeding 40%.
Traditional Site-Based Trial
- Heavy CRO fees & site initiation costs
- Complex eCRFs for hospital staff
- Mandatory in-person follow-up visits
- High patient attrition over 12-24 months
Decentralised ePRO Model
- Fraction of the cost per enrolled patient
- Minimal administrative burden on participating clinics
- Direct-to-patient digital delivery via SMS/email
- ~85% longitudinal completion rates
How to structure a lightweight decentralised study
To collect robust, auditable real-world evidence without excessive overhead, focus on four design principles:
1. Web-first ePRO without app barriers
Deliver validated questionnaires via one-click secure links sent directly to the participant's phone. Requiring app store downloads or account logins introduces friction that immediately harms compliance.
2. Automated longitudinal reminder cadence
Post-market follow-up often spans two to five years. An automated reminder workflow ensures questionnaires arrive exactly at scheduled milestones (e.g. 6 weeks, 6 months, 1 year, 2 years) with gentle automated chasing for non-responders.
3. Exact product-level tagging
Ensure every enrolled participant is tagged with the specific product SKU, batch number, or anatomical indication at the time of treatment. Notified bodies and health economists need evidence on your specific device, not generic class-level data.
4. Clear ethical and audit governance
Ensure your electronic consent, data storage, and audit logs satisfy UK GDPR, GCP (Good Clinical Practice), and relevant medical device post-market surveillance requirements.
How Patient Watch supports clinical studies & registries
We help medical device manufacturers, biotech companies, and researchers run efficient, product-linked outcome registries.
Capabilities for studies and PMCF
- Validated outcome library. Standardised implementations of Oxford scores, KOOS, WOMAC, QuickDASH, MOXFQ, and visual analogue scales.
- High participant retention (~85%). Our timed reminder cadence ensures consistent follow-up across multi-year observational periods (directional, not a contract SLA).
- Structured exports. Clean, audit-ready data tables tagged by product SKU, clinic site, and timepoint, ready for statistical analysis or regulatory dossiers.
Our take
Real-world evidence does not require multi-million pound CRO contracts. If you give patients a clean, effortless way to complete questionnaires on their phones and automate the reminder schedule, you can collect high-quality, product-linked clinical data at a fraction of the traditional cost.
Planning a study or PMCF registry?
Learn how we can set up automated ePRO collection, patient reminders, and product-linked registries for your device.
FAQ
Do notified bodies accept decentralised ePRO data?
Yes. European MDCG guidance (including MDCG 2020-7) explicitly recognises registries and real-world post-market clinical follow-up using validated electronic outcome measures, provided data integrity and protocol quality are maintained.
How is study data exported for analysis?
Data can be exported in structured CSV or Excel formats, with timestamped completions, patient identifiers, and baseline comparisons formatted for statistical packages.
Does Patient Watch replace our CRO?
No. We provide the digital capture platform, automated reminders, and data pipelines. Your internal team or clinical consultants remain responsible for study design, statistical analysis plans, and regulatory reporting.
Sources
- Regulation (EU) 2017/745 on medical devices (MDR). EUR-Lex
- MDCG 2020-7. Post-market clinical follow-up (PMCF) Plan Template. April 2020. European Commission
Guy built Patient Watch at Imperial College London for his father, an orthopaedic surgeon. Today, NHS and private clinics use Patient Watch to automate questionnaire schedules, track patient recovery after injections and surgery, and collect real-world clinical evidence.
Related articles
Digital vs traditional patient symptom tracking
A comparison of paper-based and digital symptom tracking across data quality, cost and patient participation.
How not to leave PMS to the last minute as a medical device manufacturer
Why product-linked post-market surveillance needs to start early, especially when national registries do not cover every SKU.
The data you need to sell is the data MDR already wants
How product-linked follow-up can support both post-market clinical follow-up and market-access conversations.